Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Dabigatran

Dabigatran

Direct thrombin inhibitor (oral DOAC)

DOACAFVTEAdult

Indication

NVAF β€’ VTE treatment β€’ extended VTE prevention

At a glance

INDICATIONS (CORE USE)

NVAF; VTE treatment/prevention β€” **CrCl ≀30** dose reduction; **P-gp inhibitors** contraindicated or dose-adjusted; **dialysis-removable**.

ADULT DOSE (STANDARD)

150 mg BID vs **110 mg BID** (some regions); CrCl ≀30 β†’ **75 mg BID** (US) / avoid or reduce per EU label

MAX DOSE

300 mg/day (150 mg BID) typical max

Route

PO (capsules in bottle β€” moisture sensitive)

PEDIATRIC DOSE

Pediatric formulations in some regions β€” weight-based β€” specialist

Do not miss

Must-not-miss safety points

Major warning

- **Dyspepsia** common β€” PPI may help; adherence suffers if not addressed - **P-gp inhibitors** (dronedarone, ketoconazole) β†’ contraindicated or dose-capped per label - Do not chew pellets outside approved administration methods

Indications

USE IF: NVAF/VTE when renal function and interactions permit. AVOID IF: mechanical valve, CrCl below threshold, strong P-gp interaction prohibited by label.

Primary

  • NVAF stroke prevention
  • Treatment and reduction in recurrence of VTE

Dosing

STANDARD (ADULT PO)

150 mg BID (CrCl >30 typical) β€” region-specific alternatives 110 mg BID

ADULT DOSE

CrCl **>30:** 150 mg BID (US) or 110 mg BID if bleed risk (EU-style). CrCl **15–30:** 75 mg BID US label; below 15 β†’ avoid. **P-gp inhibitor table** mandatory before starting dronedarone/ketoconazole.

PEDIATRIC DOSE

Specialist if approved.

MAX DOSE

150 mg BID.

Practical Note

Keep in original bottle; swallow whole with water; take with food to reduce dyspepsia.

Warnings

Clinical warnings

  • **Major active bleeding** or **high-risk bleeding** site β†’ do not initiate until addressed; hold if bleeding develops
  • **Duplicate anticoagulation** (DOAC + warfarin + LMWH + antiplatelet) β†’ medication reconciliation every transition β€” major bleed setup
  • **Mechanical heart valves** (especially mitral) / **moderate-severe mitral stenosis** / selected APS β†’ DOACs **contraindicated or not preferred** β€” use guideline-based therapy
  • **Pregnancy / breastfeeding** β†’ DOACs generally **avoided** in pregnancy; lactation β€” agent-specific β€” **specialist**
  • Bioprosthetic valve early post-op β€” specialist timing
  • Spinal hematoma with neuraxial

Adverse effects

  • Dyspepsia
  • bleeding
  • GI upset
  • anemia

Contraindications

  • **Active pathological / major bleeding** β€” stabilize/reverse per protocol before routine (re)start unless embedded in explicit reversal plan
  • **Upcoming invasive procedure** β€” **do not continue blindly**; document **hold/bridge/switch** with anesthesia/surgery when applicable
  • **Mechanical mitral valve / moderate–severe mitral stenosis / selected APS** β€” **DOAC label restrictions** β€” use guideline-directed alternatives
  • Active bleeding
  • Mechanical prosthetic valve (trial harm)
  • Hypersensitivity

Drug interactions

  • **Strong CYP3A4 + P-gp inhibitor** β†’ **avoid combination** or **switch agent** per label β€” do not rely on β€œmonitor only”
  • **Moderate inhibitor/inducer** β†’ **dose table per label** or **tighter bleed surveillance**
  • **NSAID or second antiplatelet added** β†’ **reassess** if surgery within days; else **clinical bleed monitoring**
  • P-gp: dronedarone, verapamil, amiodarone β€” dose adjustment per label
  • Ketoconazole β€” contraindicated with dabigatran in many labels
  • Rifampin β€” reduced efficacy

Special populations

Pediatrics

Pediatric formulations in some regions β€” weight-based β€” specialist

Pregnancy

**Pregnancy:** contraindicated. **

Lactation

** avoid.

Renal impairment

Primary renal elimination; **dialysis** removes drug β€” useful in overdose/accumulation. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + pharmacy / anticoagulation clinic):** - **CrCl >30 mL/min** β†’ **150 mg BID** (US) or **110 mg BID** if bleed-prone (some regions); renal clearance **~80%** β€” any CrCl change moves levels fast - **CrCl 10–50** β†’ **≀30** β†’ **75 mg BID** (US label) / **contraindicated** (EU) β€” **region-specific**; **never** extrapolate from Xa DOAC renal rules - **CrCl <10** / **ESRD** β†’ generally **avoid**; if exposed β†’ **HD removes ~60%** over hours β€” useful in **bleed/overdose** + guide to **idarucizumab** pathway

Hepatic impairment

Severe hepatic impairment β€” contraindicated.

Elderly

Often 110 mg BID in some regions; fall risk.

Administration

Capsules intact; do not open except pediatric pellets per label.

Monitoring

  • Monitor: - **What to check + when:** **CrCl** at baseline and with AKI, dehydration, contrast, or **P-gp** drug changes β€” drives dose/hold per label - **Escalation β€” bleeding + renal failure:** **HD removes dabigatran** β€” **idarucizumab** pathway if major + nephrology - **Escalation β€” peri-op:** Longer hold if CrCl impaired β€” verify label + anesthesia - **Starting warfarin for acute VTE** β†’ **parenteral overlap** when indicated β€” **do not stop parenteral prematurely** per guideline - **Low-risk AF elective surgery** β†’ **avoid routine bridging** β€” use thromboembolic risk stratification - Renal function at baseline and annually or after AKI
  • Recheck: - **Escalation β€” accumulation suspected:** **Hold** + reassess renal + interactions - **Procedure or neuraxial in 48–72h** β†’ **reassess anticoagulant plan** β€” DOAC hold windows **β‰ ** warfarin; document last dose time - **Interacting drug added or stopped** β†’ **recheck INR (warfarin) or reassess bleed risk / renal (DOAC)** within **48–72h** - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - **Bleeding, unexplained Hb drop, thunderclap headache, or focal neuro signs** β†’ **hold** anticoagulant + escalate per bleed protocol

Overdose / toxicity

Clinical Picture

β€’ **No bleed:** Hold β†’ reassess **CrCl** + **P-gp** drugs β†’ adjust per label β€’ **Minor bleed:** Hold β†’ supportive; **HD** if severe renal failure + ongoing effect β€’ **Major bleed:** **Idarucizumab** per protocol + supportive; **HD** adjunct when appropriate + **ICU**

Immediate Actions

β€’ **No bleed:** Hold β†’ volume/status check β†’ recheck renal + interactions β€’ **Minor bleed:** Hold β†’ local measures β†’ consider **nephrology** if HD for drug removal β€’ **Major bleed:** Stop drug β†’ **idarucizumab** + bleeding bundle β†’ **ICU**; **HD** consult if indicated

Antidote

**Antidote:** **Idarucizumab** β€” **HD** removes dabigatran (adjunct in renal failure / overdose)

Decontamination

β€’ **Early massive ingestion:** Charcoal if protected airway β€’ **Bleeding:** Triage by bleed severity first

Escalation

β€’ **Major:** **ICU** + neurosurgery if ICH; **HD** for removal/redosing questions β€’ **Refractory bleed:** Hematology + MTP

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Most **renal** of DOACs β€” recheck CrCl. β†’ **Idarucizumab** is the specific reversal. β†’ Dyspepsia β†’ adherence fix.

Clinical pearls

Switch overlap tables differ from Xa inhibitors β€” pharmacy consult. *Anticoagulation (all agents):* **A/B/C bleed tiers** β€” no bleed (hold/adjust) vs minor (hold/protocol) vs major (reversal + ICU/heme). **Warfarin:** high INR without bleed **β‰ ** major-bleed pathway; **PCC + IV K** for life-threatening bleed. **Bridging:** warfarin **slow on/off**; **parenteral overlap** when indicated for acute VTE; **no routine bridge** low-risk AF; **DOAC↔warfarin** table-specific. **Neuraxial:** explicit **last-dose β†’ procedure** documentation. Never extend therapy without indication review.

Anticoagulant safety

  • Bottle storage
  • Renal monitoring
  • Dyspepsia management

Pharmacokinetics

Prodrug dabigatran etexilate; TΒ½ ~12–17 h; renal clearance dominant.

Mechanism of action

Direct thrombin inhibitor (free and clot-bound).

Common brand names

Saudi Arabia

Pradaxa, Dabigatran

Global

(placeholder β€” verify local prefilled syringe / vial)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Reversal agents (PCC, andexanet, idarucizumab) availability and dosing vary by hospital β€” follow local protocol.
  • Perioperative interruption and bridging are **indication-specific** β€” do not copy warfarin rules onto DOACs blindly.
  • Switching between anticoagulants requires manufacturer tables + pharmacy to avoid under- or over-anticoagulation.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • CHEST / ACCP antithrombotic guidance (indication-specific)
  • ESC / AHA stroke and anticoagulation guidelines where applicable
  • ASH β€” HIT and VTE resources
  • FDA / SFDA product labeling
  • Institutional anticoagulation service / formulary
  • CHEST / ACCP antithrombotic guidance (indication-specific)
  • ESC / AHA stroke and anticoagulation guidelines where applicable
  • ASH β€” HIT and VTE resources
  • FDA / SFDA product labeling
  • Institutional anticoagulation service / formulary

Do not miss

  • Document indication, target intensity, and planned duration in the chart
  • Reassess renal/hepatic function after AKI, dehydration, or new interacting medications
  • **Renal failure accumulation:** CrCl ≀30 β†’ contraindicated or **75 mg BID** (US) β€” **dialysis removes** drug in crisis + supports **idarucizumab** decision.
  • **Wrong reversal:** Use **idarucizumab** for urgent reversal β€” PCC alone variable; **HD** adjunct when appropriate.
  • **P-gp cliff:** Ketoconazole / dronedarone / verapamil per label β€” sudden toxicity.
  • **Peri-op:** Hold **longer** if CrCl impaired (often **β‰₯48h**) vs normal renal function.
  • Mechanical valve β†’ **historical contraindication**.
  • P-gp stack without label check β†’ toxicity.
  • **Bridging & transitions (factory scaffold):**
  • **Warfarin** has **delayed onset/offset** β€” do not expect immediate effect or rapid washout like DOACs.
  • **Acute thrombosis** may require **parenteral overlap** when starting/overlapping warfarin or per label β€” **indication-specific**.
  • **Low-risk AF peri-procedure:** **do NOT routinely bridge** β€” stratify thromboembolic risk per guideline/CHEST-style tables.
  • **DOAC ↔ warfarin** switches are **indication- and table-specific** β€” pharmacy + label (valve, APS, renal).
  • **Neuraxial / high-bleed procedure:** document **last dose**, **ASRA/institutional** windows, **restart** only when hemostasis secure.
  • Bottle storage
  • Renal monitoring
  • Dyspepsia management